Clyde Biosciences Limited
- Incorporated
- 7 March 2012 (14 years)
- Previously known as
- Dunwilco (1739) Limited (until 19 July 2012)This list may be incomplete. See all names on Companies House
- Industry
- Research and experimental development on biotechnology (72110)
- Accounts type
- Total exemption full
- Region
- Scotland
- Address
- Biocity ScotlandBo'Ness RoadMotherwellML1 5UH
Filing status
- Accounts due
- 30 April 2027
- Last accounts
- 31 July 2025
- Conf. stmt due
- 12 March 2027
- Last conf. stmt
- 26 February 2026
Charges
- Total
- 2
- Outstanding
- 2
- Part satisfied
- 0
- Satisfied
- 0
Officers
Not loaded yet. See them on Companies House
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 16 March 2021
Owns 50–75% of shares
Holds 50–75% of voting rights
Private Company Limited By Shares
Reg. no. Sc437985
Former controllers (1)
21 March 2021
Ceased Epidarex Capital Management LLP — Owns 25–50% of shares
Group structure 20 companies
Ownership group derived from the Companies House PSC register
Eif Co-Invest LP Has significant influence or control
Epidarex Capital II, LP Has significant influence or control
Edinburgh Molecular Imaging Limited Owns 25–50% of shares
Epidarex Capital Iii UK, LP Has significant influence or control
Epidarex Exeed Limited Owns 75–100% of shares
Lario Therapeutics Limited Owns 50–75% of shares
Macomics Ltd Owns 25–50% of shares
Rinn Therapeutics Limited Owns 75–100% of shares
Epidarex Capital IV, LP Has significant influence or control
Epidarex Capital Partners Limited Owns 75–100% of shares
Adorx Therapeutics Limited Owns 50–75% of shares
Clyde Biosciences Limited This company Owns 50–75% of shares
Epidarex Capital II GP, LP Part right to 75–100% of surplus assets
Epidarex Capital Iii UK GP, LP Part right to 75–100% of surplus assets
Epidarex Capital UK GP, LLP Holds 25–50% of voting rights
Epx II Co-Invest LP Right to appoint and remove a person
Epidarex Partners Limited Owns 75–100% of shares
Financials
Balance sheet as at 31 July 2025 · total exemption full accounts
- Net Assets
- (£1,585,061)
- Cash
- £220,857
- Employees
- 9
Trend
Net Assets
Balance sheet detail
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Fixed Assets | £120,125 | £0 | £339 | £1,040 | £7,762 | £32,665 | |
| Current Assets | £88,112 | £182,061 | |||||
| Debtors | £52,570 | £53,077 | |||||
| Cash | £220,857 | £164,761 | £228,223 | £224,940 | £157,341 | £35,542 | £128,984 |
| Creditors (< 1 year) | £1,314,202 | £951,326 | £1,114,392 | £640,071 | £496,462 | £394,117 | £224,935 |
| Creditors (> 1 year) | £990,000 | £1,007,855 | £778,237 | £1,044,619 | £1,039,113 | £800,000 | £750,000 |
| Net Current Assets | (£306,005) | (£42,874) | |||||
| Net Assets | (£1,585,061) | (£1,680,195) | (£1,542,172) | (£1,278,858) | (£1,244,960) | (£1,098,243) | (£760,209) |
| Shareholder Funds | (£1,585,061) | (£1,680,195) | (£1,542,172) | (£1,278,858) | (£1,244,960) | (£1,098,243) | (£760,209) |
What Clyde Biosciences say about themselves
“Clyde Biosciences CellOPTIQ platform is the leading cardiomyocyte assay for safety and efficacy. Helping to bring better, safer drugs to market, we're an official member of CiPA”
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 28 April 2026 | Total exemption full accounts | 31 July 2025 | ||
| 12 March 2026 | Cessation of a person with significant control | |||
| 10 March 2026 | Notification of a person with significant control | |||
| 10 March 2026 | Cessation of a person with significant control | |||
| 26 February 2026 | Confirmation statement with updates | 26 February 2026 |
Some other companies at this address
Other companies in this industry
Edinburgh
Cambridge
Cambridge
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →